Neutralizing Antibodies to Human Endothelin-1 for Alport Syndrome Treatment
Summary
The USPTO has published Application US20260109760A1, filed October 21, 2025, covering antibodies and functional equivalents capable of neutralizing human endothelin-1. The application names Dominic Cosgrove as inventor and specifies use in treating disease conditions associated with endothelin-1 activation, including Alport syndrome. The patent falls under CPC classifications including C07K 16/26 and A61K 39/3955, indicating therapeutic antibody applications.
“This application provides antibodies and functional equivalents thereof which are capable of neutralizing endothelin-1, as well as their use in the treatment of disease conditions associated with endothelin-1 activation, such as Alport syndrome.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 211 changes logged to date.
What changed
The USPTO has published patent application US20260109760A1, a therapeutic antibody filing covering antibodies and functional equivalents that neutralize human endothelin-1. The application lists Dominic Cosgrove as inventor, with a filing date of October 21, 2025, and application number 19364408. The claimed invention extends to use of these antibodies in treating disease conditions associated with endothelin-1 activation, specifically citing Alport syndrome as a target indication.
Pharmaceutical and biotechnology companies developing endothelin pathway therapeutics should review this filing for potential freedom-to-operate considerations, particularly for therapies targeting renal diseases linked to endothelin-1 activation. The application's broad antibody claims and functional equivalence language may capture downstream therapeutic applications in the Alport syndrome treatment space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NEUTRALIZING ANTIBODIES TO HUMAN ENDOTHELIN
Application US20260109760A1 Kind: A1 Apr 23, 2026
Inventors
Dominic Cosgrove
Abstract
This application provides antibodies and functional equivalents thereof which are capable of neutralizing endothelin-1, as well as their use in the treatment of disease conditions associated with endothelin-1 activation, such as Alport syndrome.
CPC Classifications
C07K 16/26 A61K 39/3955 A61P 9/08 A61P 13/12 A61K 2039/505 C07K 14/57536 C07K 2317/21 C07K 2317/52 C07K 2317/76 C07K 2317/92 C12N 5/12
Filing Date
2025-10-21
Application No.
19364408
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.